Table 1 Characteristics of patients with immune checkpoint inhibitors in head and neck cancer
HNSCC (n = 35) | NPC (n = 11) | |||
|---|---|---|---|---|
Age (years) | 57.8 (39–73) | 47.4 (16–74) | ||
Sex | ||||
Male | 25 (71.4) | 9 (81.8) | ||
Female | 10 (28.6) | 2 (18.2) | ||
Smoking | ||||
Current | 7 (20.0) | 3 (27.3) | ||
Former | 15 (42.9) | 3 (27.3) | ||
Never | 13 (37.1) | 5 (45.5) | ||
ECOG | ||||
1 | 27 (77.1) | 11 (100.0) | ||
2 | 8 (22.9) | 0 (0.0) | ||
Primary tumor location | Hypopharynx/Larynx | 5 | Nasopharynx | 11 |
Oropharynx/Oral cavity | 15 | |||
Nasal cavity/Paranasal sinuses | 12 | |||
Others | 3 | |||
Histology | SQ | 32 (91.4) | Non-keratinizing carcinoma | 8 (72.7) |
Others | 3 (8.6) | Others | 3 (27.3) | |
HPV (oropharynx/oral cavity) | EBV | |||
Positive | 5 (33.3) | 8 (72.7) | ||
Negative | 7 (46.7) | 1 (9.1) | ||
NA | 3 (20.0) | 2 (18.2) | ||
PD-L1 22C3 (CPS) | ||||
< 1 | 3 | 2 | ||
≥ 1 | 12 (≥ 20:8) | 6 (≥ 20:3) | ||
NA | 20 | 3 | ||
Prior treatment | ||||
Surgery → CCRT/RT | 14 (40.0) | 0 | ||
CCRT/RT → Surgery | 4 (11.4) | 0 | ||
CCRT | 10 (28.6) | 6 (54.5) | ||
RT | 5 (14.3) | 1 (9.1) | ||
Induction chemotherapy | 9 (25.7) | 1 (9.1) | ||
Adjuvant chemotherapy | 1 (2.9) | 2 (18.2) | ||
Platinum-refractory | ||||
Yes | 29 (82.9) | 10 (90.9) | ||
No | 5 (14.3) | 1 (9.1) | ||
No exposure to platinum | 1 (2.9) | 0 (0.0) | ||
Prior palliative chemotherapy lines | 1 (0–4) | 2 (1–4) | ||
Prior Cetuximab + Platinum | 13 (37.1) | 0 (0.0) | ||
Immunotherapy | ||||
Nivolumab | 29 (82.9) | 3 (27.3) | ||
Pembrolizumab | 6 (17.1) | 8 (72.7) | ||
No. of cycles | 3 (1–19) | 3 (1–24) | ||